Immunogenicity of Seasonal Influenza by Delivery Directly to Ileum

Phase 1

Completed

• Conditions: Seasonal Influenza
• Interventions: Biological: VXA-A1.1

• Registration Number: NCT01761123
• Lead Sponsor: Vaxart

Brief Summary

the purpose of the study is to determine the safety and tolerability of VXA-A1.1, an adjuvanted adenoviral based influenza vaccine, when delivery is targeted to the ileum, using a radio controlled capsule. The secondary objective is to evaluate the immune response (cellular and humoral) of two doses of VXA-A1.1 oral vaccine.

Detailed Description

Not available

Study Timeline

• Study Start: 2013-01
• Study First Submitted: 2013-01-02
• Study First Submitted QC: 2013-01-03
• Study First Posted: 2013-01-04
• Primary Completion: 2014-10
• Study Completion: 2014-10
• Status Verified: 2014-12
• Last Update Submitted: 2014-12-08
• Last Update Posted: 2014-12-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 37

Inclusion Criteria

• Able and willing to complete informed consent
• Healthy, as established by medical history, physical exam, and laboratory assessments
• Has normal bowel movements
• Willing to abstain from caffeine and xanthine containing substances for 24 hours before procedure until after discharge

Read More

Exclusion Criteria

• Not able to donate up to 550 ml of blood over several months
• Exposure to an investigational drug or vaccine 8 weeks prior to study
• Abnormal ECG findings
• History of irritable bowl or any other inflammatory gastrointestinal disorder
• Any individual with increased risk for bowl obstruction
• Radiation exposure above target values 50 mSv within the past 30 days or a cumulative dose above 150 mSV in the past 12 months
• History of substance abuse
• Subject unwilling to use an approved method of contraception during study and for 2 months after study
• Positive for HCV, HIV, or HBV
• Presence of implantable device that is sensitive to radio frequencies ( e.g. pacemakers)
• History of autoimmune disorder, or an immunosuppressive disorder
• Stool sample with occult blood at baseline
• Any other medical, psychiatric, social condition, or occupation, in the judgement of the investigator is a contraindication to the compliance of the protocol or informed consent

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
VXA-A1.1	VXA-A1.1	Intestinal Delivery

Primary Outcome Measures

Name	Time	Method
Safety	1 year	Frequency and magnitude of adverse events

Secondary Outcome Measures

Name	Time	Method
Immunogenicity	1 year	Antibody and T cell responses to HA

Trial Locations

Locations (1)

Scintipharma; 🇺🇸 Lexington, Kentucky, United States